<p>Discussion of the RE-LY trial subgroup for the secondary prevention of stroke, and phase 2 results of gene therapy for Parkinson's disease.</p>

Discussion of the RE-LY trial subgroup for the secondary prevention of stroke, and phase 2 results of gene therapy for Parkinson's disease.

The Lancet Neurology: November 16, 2010

The Lancet Neurology is a monthly journal, renowned for the publication of high-quality peer-reviewed research, reviews, and analysis from around the world. In the monthly podcasts, editors of the journal discuss highlights of the current issue, with occasional interviews with an author of a key article.

Share The Lancet Neurology: November 16, 2010

Sign up to save your podcasts

The Lancet Neurology: November 16, 2010

The Lancet Neurology: November 16, 2010